Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
US-based cancer immunotherapy developer NexImmune filed for an $86.3m initial public offering on the Nasdaq Global Market on Tuesday that would give pharmaceutical firms Pfizer and Amgen the chance to exit. NexImmune is working on immunotherapies based on a nanotechnology platform developed at Johns Hopkins University that are intended to leverage nanoparticles that function as…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.